Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 20, 2007
- FPMAJ Calls For 3-Level Premiums for Innovativeness
August 20, 2007
- SELF-MEDICATION NEWS IN BRIEF
August 20, 2007
- Fixed-Point ADR Observation Project to Be Expanded: New SD Director
August 20, 2007
- Bayer Yakuhin to Focus on Specialty Drugs
August 20, 2007
- Summary of FPMAJ's Opinions on NHI Drug Pricing System
August 20, 2007
- Bayer Launches l'strogel without NHI Price Listing
August 20, 2007
- Number of Essential GCP Documents to Be Halved
August 20, 2007
- Takeda to License CCR5 Antagonists to Tobira Therapeutics
August 20, 2007
- Takeda, Santhera Extend Marketing Collaboration in EU for SNT-MC17
August 20, 2007
- Astellas Reorganizes European Business Functions
August 20, 2007
- REGULATORY NEWS IN BRIEF(1)
August 20, 2007
- Chugai: Half-Year Sales Up 12%, Ordinary Profits Up 30.5%
August 20, 2007
- REGULATORY NEWS IN BRIEF(2)
August 20, 2007
- Takeda, Taiyo in Dispute over Recall of Pansporin
August 20, 2007
- Nippon Shinyaku to Create "Monitor System" to Have New Compounds Assessed by Outside Experts
August 20, 2007
- BUSINESS NEWS IN BRIEF
August 20, 2007
- WC6 on Alternatives and Animal Use in Life Sciences to Be Held in Tokyo
August 20, 2007
- TOPICS／ACTOS Offers Safety Profile: Takeda
August 20, 2007
- R&D NEWS IN BRIEF
August 20, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…